XORTX to Present at BIO International Convention 2024
04 6월 2024 - 9:30PM
XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX |
TSXV: XRTX | Frankfurt: ANU), a late stage clinical pharmaceutical
company focused on developing innovative therapies to treat
progressive kidney disease, is pleased to announce its
participation in the
BIO International
Convention 2024, being held June 3rd through 6th, 2024. Dr. Allen
Davidoff, XORTX’s CEO, will present an overview on the Company,
including the Company’s progress to date and planned future
regulatory and clinical activities.
Dr. Allen Davidoff,
CEO of XORTX, stated, “This will be the second time that XORTX has
been invited to present at the BIO International Convention. This
presentation and accompanying meetings represent an opportunity to
continue outreach to pharmaceutical partners, licensing contacts
and industry partners. XORTX looks forward to a busy, productive
week with more than 25 scheduled meetings.”
The four-day biotechnology and pharmaceutical
science conference will be held at the San Diego Convention Center.
The presentation by CEO of XORTX, Dr. Allen Davidoff will take
place, on Tuesday, June 4th at 3:30 pm Theater 1. The presentation
will not be available by webcast.
Pharmaceutical or
biotechnology partners can schedule one-on-one meetings with Dr.
Allen Davidoff by registering with BIO International and then
proceeding through to the BIO International 2024 1-on-1
meeting platform.
About XORTX Therapeutics
Inc.
XORTX is a pharmaceutical company with two
clinically advanced products in development: 1) our lead, XRx-008
program for ADPKD; and 2) our secondary program in XRx-101 for
acute kidney and other acute organ injury associated with
Respiratory Viral infection. In addition, XRx-225 is a pre-clinical
stage program for Type 2 Diabetic Nephropathy. XORTX is working to
advance its clinical development stage products that target
aberrant purine metabolism and xanthine oxidase to decrease or
inhibit production of uric acid. At XORTX, we are dedicated to
developing medications to improve the quality of life and future
health of patients with kidney disease. Additional information on
XORTX is available at www.xortx.com.
For more information, please contact:
Allen
Davidoff, CEO |
|
Nick
Rigopulos, Director of Communications |
adavidoff@xortx.com or +1 403 455 7727 |
|
nick@alpineequityadv.com or +1 617 901 0785 |
|
|
|
Kim Golodetz, LHA Investor Relations |
|
|
kgolodetz@lhai.com or +1 212 838 3777 |
|
|
|
|
|
Neither the TSX Venture Exchange nor Nasdaq has
approved or disapproved the contents of this news release. No stock
exchange, securities commission or other regulatory authority has
approved or disapproved the information contained herein.
Forward Looking Statements
This press release
contains express or implied forward-looking statements pursuant to
applicable securities laws. These forward-looking statements and
their implications are based on the current expectations of the
management of XORTX only, and are subject to a number of factors
and uncertainties that could cause actual results to differ
materially from those described in the forward-looking statements.
Except as otherwise required by applicable law and stock exchange
rules, XORTX undertakes no obligation to publicly release any
revisions to these forward-looking statements to reflect events or
circumstances after the date hereof or to reflect the occurrence of
unanticipated events. More detailed information about the risks and
uncertainties affecting XORTX is contained under the heading “Risk
Factors” in XORTX’s Annual Report on Form 20-F filed with the SEC,
which is available on the SEC's website, www.sec.gov (including any
documents forming a part thereof or incorporated by reference
therein), as well as in our reports, public disclosure documents
and other filings with the securities commissions and other
regulatory bodies in Canada, which are available on the SEDAR+
website, www.sedarplus.ca.
Xortx Therapeutics (TSXV:XRTX)
과거 데이터 주식 차트
부터 9월(9) 2024 으로 10월(10) 2024
Xortx Therapeutics (TSXV:XRTX)
과거 데이터 주식 차트
부터 10월(10) 2023 으로 10월(10) 2024